2023-03-07 10:52:56 ET
A Virginia-based %Biotech firm is finding early success on Tuesday after the company provided an update on its regulatory strategy for AD04. According to the release, the company will pursue paths towards US and Europe approvals and said market research suggests pricing could be more than double prior assumptions.
This news sent shares of %AdialPharmaceuticals () soaring during premarket action, with traders currently willing to buy shares of this micro cap at $0.60/share (+42.86% implied open for sellers) at the time of writing. It should be an excited session for this stock!
Adial Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company develops prescription medications for addiction and related disorders. Its lead product is AD04, which is for the treatment of alcohol use disorder.